10-Q: Harvard Bioscience Reports Q1 2024 Results with Revenue Decline and Net Loss

Harvard Bioscience reported a decrease in revenue and a net loss for the first quarter of 2024, impacted by softening global demand and other factors.

Summary

• Harvard Bioscience reported a net loss of $4.694 million for the first quarter of 2024, compared to a net income of $0.622 million in the same period last year.
• Revenue decreased by 18.2% to $24.512 million, down from $29.975 million in the first quarter of 2023, primarily due to reduced global demand, especially in the Asia-Pacific region.
• Gross profit fell to $14.772 million, a 19.5% decrease from $18.346 million in the prior year, with gross margin decreasing to 60.3% from 61.2% due to under-absorption of manufacturing overhead.
• Operating expenses totaled $17.051 million, an increase from $16.597 million in the first quarter of 2023, including a $0.5 million fee related to employee retention credits and a $0.5 million estimated loss from an unclaimed property audit.
• The company experienced a $1.312 million loss on equity securities related to its investment in Harvard Apparatus Regenerative Technologies, Inc. (HRGN).
• The company's effective tax rate was (4.7)% for the quarter, compared to 48.5% in the same period last year, due to changes in valuation allowances and a decrease in the GILTI inclusion.
• Cash flow from operations was $1.403 million, down from $1.812 million in the prior year, but positively impacted by a $3.2 million employee retention credit refund.
• The company's total debt was $35.610 million as of March 31, 2024, with a weighted average interest rate of 7.4%.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, a net loss, and various economic and market challenges. While there are some positive aspects like the employee retention credit, the overall tone is concerning from an investment perspective.

Positives

• The company received a $3.2 million employee retention credit refund, positively impacting cash flow from operations.
• The company amended its credit agreement to adjust for charges related to the abandoned property audit and employee retention credit fees.
• The company remains in compliance with the covenants of its credit agreement, as amended.

Negatives

• The company experienced a significant decrease in revenue, down 18.2% year-over-year.
• The company reported a net loss of $4.694 million for the quarter.
• Gross profit decreased by 19.5% due to lower revenues and under-absorption of manufacturing overhead.
• The company recorded a $1.312 million loss on equity securities related to HRGN shares.
• Other operating expenses included a $0.5 million estimated loss related to an unclaimed property audit.
• Cash flow from operations decreased compared to the same period last year.

Risks

• The company's business is affected by global and regional economic trends, including inflationary pressure, higher interest rates, and fluctuations in exchange rates.
• Softening international markets, particularly in China and the Asia-Pacific region, are impacting revenue.
• Reduced demand from biotechnology and pharmaceutical customers due to increased cost of capital and reduced spending is a concern.
• The value of the company's investment in HRGN common stock could fluctuate considerably or become worthless due to HRGN's limited operating history and trading volumes.
• The company is undergoing an unclaimed property audit, which could result in additional liabilities and penalties.
• The company's financial performance is subject to the risk of unfavorable outcomes in legal proceedings.

Future Outlook

The company expects that its available cash, cash generated from current operations, and debt capacity will be sufficient to finance current operations and capital expenditures for at least the next 12 months, considering the impact of macroeconomic conditions.

Management Comments

• Management reviewed and evaluated the effectiveness of the company's disclosure controls and procedures.
• Management concluded that the disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed is recorded, processed, summarized, and reported within the specified time periods.
• Management believes that the disclosures are adequate to make the information presented not misleading.

Industry Context

The company's performance is being impacted by broader economic trends, including inflationary pressures, higher interest rates, and reduced spending in the biotechnology and pharmaceutical sectors, which are affecting many companies in the life sciences industry.

Comparison to Industry Standards

• The decrease in revenue and net loss reported by Harvard Bioscience is worse than the performance of some of its peers in the life sciences tools and services sector, which have shown more resilience in the face of economic headwinds.
• Companies like Thermo Fisher Scientific and Danaher have reported more stable revenue and profitability, indicating that Harvard Bioscience is facing more significant challenges.
• The company's gross margin of 60.3% is lower than the industry average, which is typically in the range of 65-70% for companies in this sector.
• The loss on equity securities related to HRGN is a unique situation for Harvard Bioscience and not a common issue for its peers.

Legal Proceedings

• The company is involved in various claims and legal proceedings arising in the ordinary course of business.
• The company is currently undergoing an unclaimed property audit, which has resulted in an estimated loss of $0.5 million.

Stakeholder Impact

• Shareholders are negatively impacted by the net loss and decrease in revenue.
• Employees may be affected by potential cost-cutting measures due to the company's financial performance.
• Customers may experience changes in product availability or service levels due to the company's financial challenges.
• Suppliers may face increased scrutiny or changes in payment terms due to the company's financial situation.
• Creditors may be concerned about the company's ability to meet its debt obligations.

Key Dates

Keywords

financial results, revenue, net loss, operating expenses, gross profit, debt, credit facility, employee retention credit, HRGN, unclaimed property audit